2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Immunology, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5300 Zanubrutinib plus obinutuzumab as chemotherapy-free first-line therapy for older patients with mantle cell lymphoma: Results from a multicenter Phase 2 study

Yanan Zhu, Yufei Lv2, Chunmei Yang, MD3, Xingnong Ye4, Xiang Zhang5, Juying Wei6, Ying Lin, MD7, Lixia Sheng, MD8, Yanhong Tong9, Jie Jin, MD10, Wen-Juan Yu, MD11
1 The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou, China
2 The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou, China
3 The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou, China
4 The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou, China
5 The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou, China
6 The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou, China
7 The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China
8 The First Affiliated Hospital of Ningbo University, ningbo, China
9 The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou, China
10 The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou, China
11 The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou, China

Background:
Older patients with mantle cell lymphoma (MCL) frequently have comorbidities, impaired performance status, and limited tolerance to conventional intensive chemoimmunotherapy. Effective chemotherapy-free regimens are therefore needed for this population. We evaluated the efficacy and safety of zanubrutinib plus obinutuzumab as first-line treatment for older patients with MCL.

Methods:
This investigator-initiated, open-label, multicenter, single-arm phase 2 study (ChiCTR2300071433) enrolled patients aged ≥65 years with previously untreated, pathologically confirmed MCL. Patients with blastoid or pleomorphic histology were excluded. Obinutuzumab was administered intravenously at 1000 mg on days 1, 8, and 15 of cycle 1 and on day 1 of cycles 2–4, with each cycle lasting 28 days. Zanubrutinib was initiated at 160 mg orally twice daily from cycle 2. After induction, patients achieving complete response (CR) received zanubrutinib maintenance, whereas those achieving partial response (PR) received 2 additional cycles of obinutuzumab plus zanubrutinib followed by zanubrutinib maintenance. Zanubrutinib was continued until disease progression, unacceptable toxicity, or treatment discontinuation. The primary endpoint was CR rate; secondary endpoints included overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety.

Results:
A total of 49 patients were enrolled, with a median age of 73 years. Bone marrow involvement was present in 34 patients (69.4%), and 14 (28.6%) had high-risk simplified Mantle Cell Lymphoma International Prognostic Index scores. Twenty-three patients (46.9%) had a Ki-67 index ≥30%. Among 32 patients with available next-generation sequencing results, 7 (21.9%) harbored TP53 mutations. Among 45 efficacy-evaluable patients assessed by PET-CT, 36 achieved a complete response and 5 achieved a partial response, yielding a best complete response rate of 80.0% and an overall response rate of 91.1%. At a median follow-up of 12 months, median progression-free survival and overall survival had not been reached. Two deaths were reported, including one due to disease progression and one due to COVID-19. Most adverse events were grade 1–2. Grade 2 infusion-related reactions during the first obinutuzumab infusion occurred in 3 patients, while 6 patients experienced grade 3–4 thrombocytopenia during the first obinutuzumab cycle. One patient developed new-onset paroxysmal atrial fibrillation, and one experienced grade 1 gastrointestinal bleeding.

Conclusions:
Zanubrutinib plus obinutuzumab produced a high CR rate and ORR, with a manageable safety profile, in older patients with previously untreated MCL. These findings support further evaluation of this chemotherapy-free first-line strategy. Longer follow-up is required to determine the durability of response and long-term survival outcomes.

Yanan Zhu: No relevant conflicts of interest to declare.